Bors, Sacha
Abler, Daniel
Dietz, Matthieu
Andrearczyk, Vincent
Fageot, Julien
Nicod-Lalonde, Marie
Schaefer, Niklaus
DeKemp, Robert
Kamani, Christel H.
Prior, John O.
Depeursinge, Adrien
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (205320_179069, 205320_219430)
CHUV Lundin Center for Neuro-oncology, Switzerland
Swiss Cancer Research Foundation (KFS-5549-02-2022-R)
Hasler Stiftung (21042)
Article History
Received: 30 August 2023
Accepted: 18 April 2024
First Online: 26 April 2024
Competing interests
: R.D.K. receives royalty revenues from Rubidium-82 PET technologies licensed to Jubilant DraxImage and INVIA Medical Solutions. All other authors do not possess any conflict of interest.